Company intelligence / Profile preview
CSPC ZhongQi Pharmaceutical Technology
Shijiazhuang, Hebei, Chinacspc.com.hk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has several late-stage clinical programs and some approved products in China. Its portfolio includes small molecules and biologics targeting oncology, metabolic disorders, cardiovascular disease, psychiatry/neurology, and respiratory conditions. Notable recent approvals include PD‑1 inhibitor and IL‑4Rα inhibitor therapies for oncology and respiratory indications.
- Therapeutic areas
- PulmonologyPsychiatryCardiovascularMetabolic DisordersOncology
- Modalities
- Small molecule drugsMonoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Liposomal drugsSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
Beyond the preview
Go deeper on CSPC ZhongQi Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSPC ZhongQi Pharmaceutical Technology.